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Abstract
Recently developed technologies have enabled multi-well measurement of O2 consumption, facilitating the rate of
mitochondrial research, particularly regarding the mechanism of action of drugs and proteins that modulate metabolism.
Among these technologies, the Seahorse XF24 Analyzer was designed for use with intact cells attached in a monolayer to a
multi-well tissue culture plate. In order to have a high throughput assay system in which both energy demand and substrate
availability can be tightly controlled, we have developed a protocol to expand the application of the XF24 Analyzer to
include isolated mitochondria. Acquisition of optimal rates requires assay conditions that are unexpectedly distinct from
those of conventional polarography. The optimized conditions, derived from experiments with isolated mouse liver
mitochondria, allow multi-well assessment of rates of respiration and proton production by mitochondria attached to the
bottom of the XF assay plate, and require extremely small quantities of material (1–10 mg of mitochondrial protein per well).
Sequential measurement of basal, State 3, State 4, and uncoupler-stimulated respiration can be made in each well through
additions of reagents from the injection ports. We describe optimization and validation of this technique using isolated
mouse liver and rat heart mitochondria, and apply the approach to discover that inclusion of phosphatase inhibitors in the
preparation of the heart mitochondria results in a specific decrease in rates of Complex I-dependent respiration. We believe
this new technique will be particularly useful for drug screening and for generating previously unobtainable respiratory data
on small mitochondrial samples.
Citation: Rogers GW, Brand MD, Petrosyan S, Ashok D, Elorza AA, et al. (2011) High Throughput Microplate Respiratory Measurements Using Minimal Quantities
Of Isolated Mitochondria. PLoS ONE 6(7): e21746. doi:10.1371/journal.pone.0021746
Editor: Alicia J. Kowaltowski, Instituto de Quı ´mica - Universidade de Sa ˜o Paulo, Brazil
Received April 4, 2011; Accepted June 6, 2011; Published July 25, 2011
Copyright:  2011 Rogers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by the American Diabetes Association 1-08-RA-139, National Institutes of Health 2 P01 DK054441-09 (ANM) and National
Institutes of Health P01 AG025901 and PL1 AG032118 (MDB). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have the following competing interest: George W. Rogers and David A. Ferrick are current employees of Seahorse Bioscience.
Dr. Alvaro A. Elorza is a former employee of Seahorse Bioscience. There are no patents, products in development or marketed products to declare. However,
Seahorse Bioscience produces a product, the XF24 analyzer, that is used for development of the approach described in this manuscript. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: anmurphy@ucsd.edu
¤ Current address: Department of Biology, Universidad Andre ´s Bello, Santiago, Chile
Introduction
Enhanced appreciation of the role of altered mitochondrial
function in metabolic and cardiovascular disease, tumorigenesis,
aging and degenerative diseases, and cell signaling has stimulated
the development of a variety of new approaches for the assessment
of mitochondrial function [1–4]. As the field has moved rapidly
toward the discovery of mitochondrial-related molecular mecha-
nisms underlying disease, as well as drugs to prevent or reverse
disease development [5–12], the demand for more flexible and
higher throughput methods of assessing mitochondrial function
has increased. As well, the importance of screening potential drug
candidates for mitochondrial toxicity is being recognized [13].
Measurement of rates of O2 consumption are extremely valuable
in this regard, as electron transport and oxidative phosphorylation
reflect the concerted function of both the mitochondrial and
nuclear genomes to express functional components of oxidative
phosphorylation. In addition, intact cell respiration reflects the
influence of multiple hormonal effects, regulated transporters and
pathways, and signaling cascades, and is a telling measure of the
overall health of cells, particularly due to the susceptibility of
mitochondria to oxidative injury.
In recent years, a number of methodologies have been developed
to enable more efficient and higher throughput acquisition of O2
consumption data [1–2,4]. Of these, the Seahorse XF24 Analyzer
was developed to assay cultured cells in a conventional microplate
format [4], representing a significant advance in throughput for
assessment of cell monolayers rather than cell suspensions as
typically done with conventional Clark electrode-based methods.
There are strengths and weaknesses of measurements of intact
cell respiration versus isolated mitochondria. The rate of oxygen
consumption by intact cells reflects a complex interplay of
biological parameters, including the rates of energy demand and
production, as well as the nature, availability, and transport of
oxidizable substrates, the effects of signaling cascades that impinge
on mitochondrial function, and the overall mass/volume of
mitochondria per cell. With intact cells, the endogenous rate of
respiration can be measured, as well as state 4o (resting respiration
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tion. However, an observed change in the rates of respiration of
intact cells (e.g. as a function of treatment with a drug or altered
expression of a gene of interest) can be somewhat difficult to
interpret. A change in intact cell respiration may owe to multiple
potential alterations that cannot be distinguished without further
experimentation, including the rate of ATP utilization, and the
transport, storage and mobilization of added and endogenous
substrates. As a result, it is often desirable and most informative to
also collect respiratory data with isolated mitochondria and thus
be able to control the availability of substrates and ADP. Assays
with isolated mitochondria allow more direct determination of the
potential site of action of a compound or gene product that affects
mitochondrial bioenergetics. Further, there are many instances in
which valuable information can be obtained from characterizing
mitochondria isolated from a limited amount of tissue, for
instance, from tissues of transgenic or knockout animal models,
or animals in which tissue-specific toxicity of drug candidates need
to be characterized.
As a result, we focused our efforts on developing an assay using
isolated mitochondria in the XF24 analyzer, and have successfully
devised a protocol that allows measurement of mitochondrial O2
consumption with as little as 1 mg of mitochondrial protein per
well in a multi-well format, facilitating the quantity of information
and minimizing the time it takes to gather respiratory data from
small tissue samples.
Methods
Materials
Fatty acid-free BSA and a protein phosphatase inhibitor cocktail
(Phosphatase Inhibitor Cocktail Set II) were purchased from EMD
Biosciences. Cell-TakH was purchased from BD Biosciences.
Purified H2O purchased from Thermo Scientific was used for
respiratory media and reagents. Bradford Assay reagent was
purchased from Bio-Rad. All other chemicals were purchased
from Sigma-Aldrich.
Reagent and Solution Preparation
Mitochondrial isolation buffer (MSHE+BSA) is composed of
70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM EGTA
and 0.5% (w/v) fatty acid-free BSA (pH 7.2). Mitochondrial assay
solution (MAS, 1X) comprises 70 mM sucrose, 220 mM mannitol,
10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA
and 0.2% (w/v) fatty acid-free BSA, pH 7.2 at 37uC. A 2–3X
stock of MAS was prepared for dilution of substrates, ADP and
respiration reagents. Stocks of succinate, malate, glutamate,
pyruvate (0.5 M) and ADP (1 M) were made in H2O and adjusted
to pH 7.2 with potassium hydroxide. Stocks of 10 mM FCCP
[carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone], 2 mM
rotenone, 5 mg/ml oligomycin and 40 mM antimycin A were
made in 95% ethanol. All reagents were stored at 220uC, except
pyruvate, which was prepared fresh on the day of each
experiment.
Isolation of Mouse Liver Mitochondria
Ethics Statement: Animal housing, euthanasia, and tissue
harvest procedures were conducted in accordance with and
approved by the UCSD Institutional Animal Care and Use
Committee (protocol #S09186) and the Buck Institute Animal
Care Committee (protocol #10180). Mitochondria from C57bl/6
(male and female) mice aged 4–6 weeks were isolated by two
similar differential centrifugation methods, based upon Schnait-
man and Greenawalt [14] or Chappell and Hansford [15].
Specifically, the liver was extracted and minced in ,10 volumes of
MSHE+BSA (4uC), and all subsequent steps of the preparation
were performed on ice. The material was rinsed several times to
remove blood. The tissue was disrupted using a drill-driven Teflon
glass homogenizer with 2–3 strokes. Homogenate was centrifuged
at 800 g for 10 min at 4uC. Following centrifugation, fat/lipid was
carefully aspirated, and the remaining supernatant was decanted
through 2 layers of cheesecloth to a separate tube and centrifuged
at 8000 g for 10 min at 4uC. After removal of the light mito-
chondrial layer, the pellet was resuspended in MSHE+BSA, and
the centrifugation was repeated. The final pellet was resuspended
in a minimal volume of MSHE+BSA. Total protein (mg/ml) was
determined using Bradford Assay reagent (Bio-Rad). Typically,
,7.5 mg of mitochondria (100 ml volume) was obtained from a
single mouse liver. In separate studies in which respiratory rates in
the Seahorse and the Rank Clark electrode system were
compared, mouse liver mitochondria were isolated according to
Chappell and Hansford [15] in 250 mM Sucrose, 5 mM Tris and
2 mM EGTA (STE) on ice. Tissue was homogenized 10 times
with a Teflon-glass homogenizer, and the homogenate was
centrifuged at 1000 g for 3 minutes (4uC). The supernatant was
collected and centrifuged at 11,600 g for 10 minutes. The pellet
was resuspended in STE after discarding the whitish layer. The
above step was repeated two times to get the final mitochondrial
pellet. 8–10 mg of mitochondrial protein was obtained from each
mouse liver and resuspended in 400–500 ml of STE.
Isolation of Rat Heart Mitochondria and Phosphatase
Inhibitor Treatment
Ethics Statement: Animal housing, euthanasia, and tissue harvest
procedures were conducted in accordance with and approved by
the UCSD Institutional Animal Care and Use Committee (protocol
#S09184). Hearts were harvested from adult male (approx. 300 g)
Sprague Dawley rats. Mitochondria from two hearts were isolated
by differential centrifugation similar to Sordahl [16]. The tissue
was minced and then disrupted with a polytron (IKA Works,
Wilmington, NC) at 4uC in MSHE containing 0.5% BSA. The
disrupted tissue was centrifuged at 27,000 g for 10 min. The pellet
was resuspended and centrifuged at 500 g, and the supernatant
filtered through cheesecloth and then centrifuged at 10,000 g. The
mitochondrial pellet was resuspended and the centrifugation was
repeated. The final pellet was resuspended in a minimal volume
of MSHE+BSA. Typically, ,2.5 mg of mitochondria (,50 ml
volume) was obtained from two rat hearts. Where indicated, the
minced tissue was split into two aliquots. To one aliquot, a 1:400
dilution of phosphatase inhibitor cocktail Set II (EMD Chemicals,
Cat. No. 524625) was included in the MSHE+BSA for the
remainder of the preparation. At this dilution, the final concentra-
tions of phosphatase inhibitors present in the isolationmedium were
0.5 mM imidazole, 0.25 mM sodium fluoride, 0.3 mM sodium
molybdate, 0.25 mM sodium orthovanadate, and 1.0 mM sodium
tartrate.
Clark Electrode Assays
Clark electrode assays performed for comparative purposes
utilized a Hansatech Oxytherm apparatus (PP Systems, Amesbury,
MA) for rat heart mitochondria or a Rank system (Rank Brothers,
Bottisham, Cambridge, England) for mouse liver mitochondria. For
rat heart mitochondria, assays were performed in parallel with the
same mitochondrial preparation, MAS, substrates and compounds
asfortheXF24assays.Typically62.5–125 mgofmitochondriawere
used in a volume of 500 ml MAS plus the appropriate substrate.
Respiration was initiated by adding mitochondria, and followed by
sequential addition of ADP, oligomycin and FCCP. Concentrations
High Throughput Mitochondrial Respiration
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used in the XF24 experiments. For mouse liver mitochondria,
assays were performed in parallel the same mitochondrial
preparation, MAS, substrates and compounds as for the XF24
assays with the following modifications: substrate was 5 mM
succinate, 2 mM rotenone and 300 mM ADP was used. Typically,
0.3 mg/ml of mitochondria were used in a volume of 2.0–3.5 ml
MAS plus the appropriate substrate. Respiration was initiated by
adding mitochondria, followed by sequential addition of ADP,
oligomycin and FCCP. Concentrations of oligomycin and FCCP
were identical to those used in the XF24 experiments. Oxygen
consumption rates were converted from nmol O/min/ml to pmol
O2/min/mg mitochondrial protein.
The XF assay using isolated mitochondria
All XF assays were performed using an XF24–3 Extracellular
Flux Analyzer (Seahorse Bioscience). The assay is based upon
fluorimetric detection of O2 and H
+ levels via solid state probes on
a sensor cartridge that lowers to within 200 microns of the well
bottom during a measurement cycle, creating a transient micro
chamber (,7 ml) [4]. After a measurement cycle, the sensor
cartridge rises, and the medium is re-oxygenated through
mechanical mixing, thus allowing repeated measurements of O2
and pH over time. The sensor cartridge is equipped with four
reagent delivery chambers per well for injecting compounds into
the wells during an assay. Either rates of O2 consumption (OCR,
oxygen consumption rate in pmoles O2/min) and changes in pH,
or absolute levels of O2 and pH can be visualized in the data
output.
A schematic diagram of the assay is presented in Fig. 1.
Compounds to be injected were prepared in 1X MAS at 10X the
final concentration required for the assay. Compounds were
loaded into the injection ports at the following volumes: Port A,
50 ml; Port B, 55 ml; Port C, 60 ml and Port D, 65 ml, which yields
an ,10X dilution for each injection. Just before attachment of the
mitochondria to the XF plate, the loaded cartridge was placed into
the XF24 instrument and calibrated.
To minimize variability between wells, mitochondria were first
diluted 10X in cold 1X MAS + substrate, then subsequently
diluted to the needed concentration required for plating. Next, 25
or 50 ml of this mitochondrial suspension was delivered to each
well (except for background correction wells) while the plate was
on ice. Note that substrate was included in the initial dilution and
was present during centrifugation, as this improved the respiratory
control ratios obtained in the assay. Centrifugation in larger
volumes of mitochondrial suspension resulted in lower maximal
respiratory rates, likely due to loss of mitochondria to the sides of
the wells. The plate was transferred to a centrifuge equipped with
a swinging bucket microplate adaptor, and was spun at 2000 g for
20 minutes at 4uC. After centrifugation, 450 or 475 ml of 1X MAS
Figure 1. Schematic flowchart for the isolated mitochondria assay using the Seahorse XF24 Analyzer. Mitochondria are diluted into 1X
MAS containing the substrate of choice. Initial conditions refer to any additives or compounds present at 1X at the start of the assay in addition to the
substrate (e.g. drug candidate, etc.).
doi:10.1371/journal.pone.0021746.g001
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mitochondria were viewed briefly under a microscope at 20X
magnification to ensure consistent adherence to the well, then
placed at 37uC for 8–10 minutes to allow the plate to warm. The
plate was then transferred to the XF24 instrument and the
experiment initiated. For comparison of adhesion with polyethy-
leneimine (PEI) and Cell-TakH, plates were coated with PEI as
described in Gerenscer et al [17] and plates were coated with Cell-
TakH per manufacture’s instructions.
Experimental Design
Two types of experiments are presented with isolated mito-
chondria. In the first, respiration by the mitochondria (5 mg/well)
was sequentially measured in a coupled state with substrate present
(basal respiration), followed by State 3 (phosphorylating respira-
tion, in the presence of ADP and substrate), State 4 (non-
phosphorylating or resting respiration) following conversion of
ADP to ATP, State 4o (induced with the addition of oligomycin),
and then maximal uncoupler-stimulated respiration (State 3u).
This allows respiratory control ratios (RCR; State 3/State 4o,o r
State 3u/State 4o) to be assessed [18–20]. Unless otherwise noted,
the substrate was 10 mM succinate plus 2 mM rotenone. Injections
were as follows: port A, 50 ml of 40 mM ADP (4 mM final); port B,
55 mlo f2 5mg/ml oligomycin (2.5 mg/ml final); port C, 60 mlo f
40 mM FCCP (4 mM final); and port D, 65 mlo f4 0mM antimycin
A( 4 mM final). The second type of experiment examined
sequential electron flow through different complexes of the
electron transport chain. With the initial presence of 5 mg mito-
chondria per well, 10 mM pyruvate, 2 mM malate and 4 mM
FCCP, injections were made as follows: port A, 50 mlo f2 0mM
rotenone (2 mM final); port B, 55 ml of 100 mM succinate (10 mM
final); port C, 60 mlo f4 0mM antimycin A (4 mM final); port D,
65 ml of 100 mM ascorbate plus 1 mM N,N,N9,N9-Tetramethyl-
p-phenylenediamine (TMPD, 10 mM and 100 mM final, respec-
tively). Typical mix and measurement cycle times for the assays are
illustrated in Table 1 and are common to all experiments
presented unless otherwise noted.
XF data treatment
XF oxygen consumption rate (OCR) raw data was transformed
using the ‘‘Level(Direct)Akos’’ algorithm that is a component of
the Seahorse XF24 1.5.0.69 software package. This algorithm is
fully described in Gerencser et al [17]. The software may be
configured to show kinetic data in a ‘‘point-to-point’’ or ‘‘middle
point’’ mode. The point-to-point mode (e.g. Figs. 2, 3) displays
OCR as a series of rates across the measurement period and can
show changes of the rate across the measurement period (e.g.
Fig 3A). The middle point mode shows a single OCR value for the
measurement period, and is the average of the point-to-point rates
(e.g. Fig. 4A) Note that if the point-to-point rates are stable
(relatively constant) across the measurement period, then point-to-
point and middle point modes will provide equivalent rate data.
All experiments described and shown were repeated at least 3
times with similar results based on respiration rates and RCR
values obtained. Figures presented are representative graphs of the
illustrated assay.
Results
Validation of the XF method
The XF24–3 Analyzer is a 24 well microplate-based instrument
that was designed to measure in real time the kinetics of O2
consumption and H
+ production of a monolayer of cells attached to
the wells of an XF24 microplate. Our aim in these studies was to
find conditions that might allow use of the XF24 with isolated
mitochondria. Following the successful introduction of centrifuga-
tion as a means to attach suspended synaptosomes to XF24
microplates [21], we used the same approach to attach mitochon-
dria to the plate by centrifugation and measured OCR. We
ultimately identified conditions that allowed for sequential mea-
surement of basal respiration (in the presence of substrate but no
ADP),State3(+ADP),State4o(+oligomycin),andState3u(+FCCP)
by the protocol described in Fig. 1, and these differ significantly
from typical conditions for conventional O2 electrode measure-
ments [22]. Table 1 outlines the general mix and measure cycle
times used for the assays. The results using 5 mg mitochondrial
protein per well in Fig. 2A (5 mg group) show the optimal result: a
steady low rate of respiration with substrate before addition of ADP;
a substantial increase in rate to a high sustained state 3 rate after
addition of ADP; a substantial decrease in rate to a low state 4o rate
after additionofoligomycin; a high stimulation byFCCP to state 3u,
and strong inhibition to a near zero rate after addition of the
complex III inhibitor, antimycin A (AA).
In Fig. 2, determination of an optimal quantity of mitochondria
per well is demonstrated, with the objectives to ensure robust
signal, minimal noise, as well as keeping OCR values within the
linear range of response of the mitochondria and within the
dynamic range of the instrument and algorithms employed to
Table 1. Mix and Measure Cycle Times.
Command Time (min) Port
Calibrate
Mix 1.0
Wait 3.0
Mix 1.0
Wait 3.0
Mix 0.5
Measure 3.0
Mix 1.0
Measure 3.0
Mix 0.5
Inject A
Mix 0.5
Measure* 3.0–6.0
Mix 1.0
Inject B
Mix 0.5
Measure 3.0
Mix 1.0
Inject C
Mix 0.5
Measure 3.0
Mix 1.0
Inject D
Mix 0.5
Measure 3.0
*Measure times for State 3 respiration may be extended beyond 3 min to
observe the transition from State 3 to State 4 due to exhaustion of ADP in the
microchamber.
doi:10.1371/journal.pone.0021746.t001
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mitochondria from 1.25–40 mg per well were attached to a plate as
described in the Experimental section and basal respiration, States
3, 4o,3 u, and non-mitochondrial O2 consumption were sequen-
tially measured. Basal rates of respiration were linear from 1.25 to
5 mg. The sequentially measured rates as ADP, oligomycin, FCCP,
and antimycin A were injected into the wells were generally linear
with respect to mg mitochondria used per well. However, for 10 mg
or greater per well, the response of the mitochondria for various
respiration states became non-linear (note 10, 20 and 40 mg
amounts in Fig. 2A). To explain this behavior, the O2 concen-
tration (oxygen tension as measured in mm Hg) values were
reviewed (Fig. 2B). These data illustrate the result of overloading
the wells, and show that with mouse liver mitochondrial samples of
10 mg or greater per well, a) O2 can be completely depleted from
the microchamber (0.0 O2 tension), and b) the system does not
have an adequate time to recover to normoxia (return to ambient
O2 tension, ,158 mm Hg) before the next measurement cycle.
These two factors prevent accurate measurement of OCR at
higher concentrations of mitochondria, with State 3 being
underestimated and apparent poor response of the mitochondria
to oligomycin and FCCP. Thus, when adapting this method to
mitochondria isolated from other species/tissues, it is critical to
ensure that an optimal amount of mitochondria are used per well.
It is suggested that basal respiratory rates be kept between 100–
200 pmol/min/well to afford the best signal-to-noise ratio and
dynamic range for the assay, and we find that, depending on tissue
and species used, 1–10 mg of isolated mitochondria is optimal for
the assay.
Our initial use of typical concentrations of ADP (,200 mM) was
unsuccessful at eliciting State 3 rates. Instead, much higher
concentrations of ADP were required to obtain stable State 3 rates.
This is due to the very small effective volume of the microchamber
(,7 ul) during the measurement cycle (see Discussion). To
investigate the effects of ADP concentration, the measurement
time for State 3 respiration was extended to 6 minutes and ADP was
titrated from 0.0 to 4.0 mM. The point-to-point rate data in Fig.3A
clearly reflects the exhaustion of ADP at lower concentrations
(0.25–1.0 mM). Thus, the transition from State 3 to State 4
respiration upon conversion of the pool of ADP to ATP is evident
(Fig. 3A), and therefore a respiratory control ratio as defined by
State 3/State 4 can be calculated. If a stable State 3 rate is desired,
Figure 2. Optimization of isolated mitochondria XF assays. 2A–B, Determination of optimal mg amount of mitochondria/well. 1.25–40 mg/well
of mouse liver mitochondria were attached to a V7 polystyrene XF24 plate and the coupling experiment was performed as described in Methods in
the presence of succinate/rotenone. Blue vertical lines denote injections of indicated compounds. 2A shows OCR for 1.25–40 mg samples. 2B shows
the absolute O2 tension (in mm Hg) in the microchamber for 1.25–40 mg samples. Note that samples at 10 mg and above show unstable State 3 rates
for OCR and depletion of O2 in the microchamber in panels A and B, respectively. Lettering within data points indicates the group identification
number.
doi:10.1371/journal.pone.0021746.g002
Figure 3. Characterization of mitochondrial activity. 3A, Titration of ADP using 5 mg mouse liver mitochondria/well. ADP (0–4 mM) was
injected via port A to initiate State 3 respiration and the measurement time was extended to 6 minutes. Note that 2–4 mM ADP is sufficient to
maintain a relatively stable State 3 respiration rate for the duration of the measurement period, while lower concentrations show exhaustion of ADP
and transition to State 4 respiration. 3B, Alkalinization of the media during phosphorylating respiration (note that unlike the OCR tracings, this data
reports absolute pH rather than a rate of change in pH).
doi:10.1371/journal.pone.0021746.g003
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measurement period of 6 minutes. Note that the decrease in rate at
lower ADP concentrations is not the result of O2 exhaustion in the
microchamber (Fig. 3A versus Fig. 2B, 5 mg). In addition, experi-
ments in which the concentration of phosphate was varied, 10 mM
provedoptimal and ensures a saturatingconcentrationofphosphate
for ATP synthesis (data not shown). Thus, the method provides the
ability to record State 3 respiration followed by exhaustion of ADP
to State 4 given an appropriate length of measurement cycle.
Another interesting aspect of the assay is the ability to monitor
changes in pH. In conventional use of the XF24, changes in
extracellular pH act as an indirect monitor of lactate production via
glycolysis[4,23–24].Viewingthecorrelating pHdata fromtheADP
titration (Fig. 3D), it is observed that an increase in pH occurs
during the phosphorylation reaction (after ADP injection) that is
quickly abrogated upon the addition of oligomycin. This reflects
that the ATP synthesis reaction consumes protons as the ADP is
phosphorylated to ATP: MgADP
2 + Pi
21.5 +0.5H
+R MgATP
22 +
H2O (assuming Pi is an approximate 50:50mixture of Pi
21 and Pi
22
at neutral pH).
A critical element of the method was to ensure that the
mitochondria adhere tightly to the wells and do not detach from
the plate during the mixing action of the instrument over the
course of the assay. While this has been previously demonstrated
using polyethyleneimine (PEI) as a surface coating [17], we wished
to test if a plate coating was necessary, or if other coatings may be
more optimal for adhesion. Four distinct methods were employed
to investigate adherence of the mitochondria to the well plate.
First, it was assessed whether repeated measurement cycles, each
associated with a mixing/reoxygenation step, resulted in a loss of
mitochondria and therefore a loss in respiratory rate. Figure 4A
(no plate coating used) illustrates via repeated measurements of
State 3 respiration (12 repeated measurements over ,50 minutes)
that the ADP-stimulated rates remain consistent throughout the
assay, strongly suggesting that mitochondria remained attached to
the well for the duration of the assay. Note that each point shows
the average OCR for each 3 minute measurement cycle (as
opposed to point-to-point rates, see ‘‘data treatment’’ in the
Methods section). Second, experiments were performed with no
coating, or plates coated with PEI or Cell-TakH. Coating with
Cell-TakH or PEI did not alter State 4o rates compared to rates
with no coating used (Fig. 4B). Third, phase contrast images of the
same well immediately before and after the experiment indicated
that there were no noticeable differences in the appearance or
Figure 4. Isolated mitochondria remain attached to the plate for the duration of the experiment. A, The coupling experiment was
performed using 5 mg mouse liver mitochondria per well as described in Methods, however, State 3 respiration was allowed to proceed for multiple
measurement periods (average OCR per measurement period shown). Note that State 3 respiration does not diminish over multiple mixing and
measuring periods, indicating that the mitochondria remain attached to the well for the duration of the assay. B, State 4o rates using different plate
coatings in the presence and absence of 0.2% BSA. No significant differences in State 4o rates were observed among different plate coatings [none,
polyethyleneimine (PEI), and Cell-TakH]. Note that the absence of BSA resulted in elevated rates of State 4o respiration, indicative of respiratory
uncoupling. C–D, Isolated mitochondria adhered to the XF24 plate as imaged by phase contrast microscopy at 20X magnification before (4C) and
after the XF assay (4D).
doi:10.1371/journal.pone.0021746.g004
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remained tightly attached to the well plate (Fig. 4C and D, no
plate coating used).
Experiments that measured any potential release of total
mitochondrial protein during the assay were performed by
comparing the total protein concentration in the supernatant of
replicate wells before and after the experiment. These parallel
assays were performed in the absence of BSA to allow accurate
quantification of small concentrations of protein. Greater than
95% of the total mitochondrial protein was adhered to the plate
before the experiment, and ,10% of total adhered protein was
detectable in the supernatant after the assay (data not shown).
It was also determined that mouse liver mitochondria required
the presence of BSA in the assay medium to prevent mitochondrial
uncoupling (Fig. 4B). State 4o rates were significantly higher in the
absence of BSA, and further experiments testing a range of 0.0 to
0.8% BSA indicated that 0.2% BSA is required to obtain minimal
basal and State 4o rates (data not shown).
We next compared the rates of mitochondrial respiration
obtained from experiments in the XF24 to those obtained in more
conventional measurements of oxygen consumption using a Clark-
type electrode. Respiratory rates (basal, State 3, State 4o, and State
3u) of isolated rat heart mitochondria oxidizing glutamate/malate
(Fig. 5A) or succinate with rotenone (Fig. 5B) measured in the
XF24 were in a similar range to those obtained using a Hansatech
Oxytherm apparatus under similar conditions (37uC in MAS
buffer). In addition, respiration rates of isolated mouse liver
mitochondria were comparable using the XF24 and a Rank
system (Fig. 5C).
Applying the XF method
To demonstrate the potential utility of this method for
determining the effects of agents on mitochondrial respiration, a
series of experiments were conducted examining 1) the level of
respiratory coupling (the ‘coupling experiment’) and 2) the
sequential determination of complex I, II, III and IV-dependent
respiration (the ‘electron flow experiment’). Fig. 6 demonstrates
the effects of known respiratory inhibitors on the pattern of
respiration. For the coupling experiment (Fig. 6A, C), mouse liver
mitochondria were incubated with substrate (10 mM succinate
+2 mM rotenone) during the centrifugation step. ADP, oligomycin,
FCCP, and antimycin A were then sequentially injected, and
measurements of OCR were taken after each injection. The
electron flow experiment (Fig. 6B, D) is designed to follow and
interrogate each complex of the electron transport chain. This
experiment begins with the mitochondria utilizing Complex I
respiration in an uncoupled state (10 mM pyruvate, 2 mM malate
plus 4 mM FCCP, final concentrations). The following compounds
(final concentrations) are then added sequentially: rotenone
(2 mM), succinate (10 mM), antimycin A (4 mM) and ascorbate/
TMPD (1 mM and 100 mM, respectively). Because oxidation of
pyruvate/malate is mediated via Complex I, injection of rotenone
inhibits this and respiration stops. Injection of succinate allows the
mitochondria to respire via Complex II, and OCR values increase.
Electron flow is then inhibited at Complex III by antimycin A, and
respiration stops as expected. Finally, addition of ascorbate and
TMPD (which act as electron donors to cytochrome C/complex
IV) elicits an increase in the OCR.
By using these two assays in tandem in a single microplate, it
now becomes possible to pinpoint sites of action of unknown
compounds (e.g. potential drug candidates) on mitochondrial
function, and this data is presented in Fig. 6A–D. To illustrate the
method, we have chosen five well-described compounds that affect
mitochondrial function to represent the ‘‘unknown compounds’’.
Each of these compounds was added to the wells as ‘‘initial
conditions’’ when the additional 450 ml of MAS + substrate was
added after the centrifugation step (Fig. 1).
Figure 6C–D show the effects of rotenone (a Complex I
inhibitor) on coupling and electron flow. As expected, there is no
effect on the OCR values in the coupling experiment, as rotenone
was already present and respiration was being driven by Complex
II-IV activity. However, it was observed in the electron flow
experiment that pyruvate/malate-dependent respiration was
inhibited at the beginning of the assay in contrast to the control,
in which robust respiration was present. The fact that the control
and the group to which rotenone was added show identical
subsequent responses upon injections B–D suggests, as anticipated,
that the remainder of the electron transport chain is functioning
properly.
The effects of including malonate or antimycin A (Fig. 6, panels
C–D or A–B, respectively) in the initial conditions of coupling and
electron flow assays are shown. Malonate is a competitive inhibitor
of succinate dehydrogenase (complex II), and antimycin A inhibits
complex III. For malonate, as anticipated, all the respiratory rates
are inhibited except for the respiration driven by pyruvate/malate
at the start of the electron flow experiment, and the ascorbate/
TMPD-driven rate mediated by complex IV. Like malonate, the
effect of antimycin A in the coupling experiment was complete
respiratory inhibition and no response to ADP, oligomycin, or
FCCP. However, unlike malonate, antimycin A prevents both
complex I- and complex II-mediated respiration due to inhibition
of complex III, resulting in complete inhibition of respiration
throughout the electron flow portion of the assay until addition of
ascorbate/TMPD, indicating that complex IV remains active.
Figure 6, panels A–B or C–D show the effects of the azide anion
or oligomycin on respiration, respectively. Azide, like carbon
monoxide and cyanide, is an inhibitor of complex IV. This is
demonstrated in both the coupling and electron flow experiments,
with reduced respiration throughout the assay. Note that while
complete inhibition is not observed due to sub-saturating concen-
trations of azide, overall respiration is decreased. Most instructive
is the fact that addition of ascorbate/TMPD could not increase
electron flow (and in turn O2 consumption) at Complex IV.
Finally, oligomycin, an inhibitor of the ATP synthase (complex V)
prevents only ATP synthesis (the ADP-stimulated rate, State 3) in
the coupling experiment, but does not affect electron flow through
the complexes under uncoupled conditions.
The coupling and electron flow experiments were also used to
demonstrate intra- and inter-assay variability. Typically, 3–5
replicate wells per group were used on a plate. Figure 7A shows
average rate data from 3 individual wells of an electron flow and a
coupling assay, with mean, standard deviation and% coefficient of
variation (CV) presented in the corresponding table. Intra-assay
rates are very consistent, with CVs of 10.3% and 4.6% for State 3
and State 4o rates, respectively. RCR values were 4.260.6 and
6.260.6 for States 3/4o and 3u/4o, respectively. Basal and State 3u
values showed #15% CVs. The electron flow assay also exhibited
consistent results, with CVs ,14%. The high CVs reported for
antimycin A (coupling) and rotenone (electron flow) treatment arise
from the very low OCR levels. To illustrate inter-assay reproduc-
ibility, the average of four different mouse liver mitochondrial
preparations (different animals/different days) are presented in
Fig. 7B. Rates of basal, State 3, and State 3u were reproducible
with low standard deviations (CVs ,20%). Expressed in more
conventional units of respiration, the State 3 rate of respiration on
succinate (8366133 pmol O2/min/5 mg mitochondrial protein,
Fig.7B) is 334654 nmolO/min/mg of mitochondrial protein. The
RCR value as calculated by State 3/State 4o over the four
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and RCR as calculated by State 3u/State 4o was 5.260.6.
We have additionally applied this methodology to test the effects
of a commercially available cocktail of protein phosphatase
inhibitors (PPI) on rat heart mitochondrial respiration. The effect
of the PPI was tested by adding a 1:400 dilution of the premixed
cocktail to the mitochondrial isolation medium immediately prior
to disruption of the tissue with the polytron, and the inhibitors
were included throughout the subsequent steps of the isolation,
and were included in the MAS during the experiment. At the
concentrations used, this cocktail would be expected to inhibit
primarily protein tyrosine phosphatases. As indicated in Fig.8,
rates of State 3, 4o, and 3u respiration with succinate (plus
rotenone) were unaffected by PPI treatment. In contrast, rates of
glutamate/malate-driven State 3 and 3u were significantly lower as
a result of the inhibitor treatment. This approximate 50%
reduction suggests that PPI treatment affects either the activity
of complex I, or the metabolism or transport of glutamate or
malate.
Discussion
We describe the development of a robust and high throughput
assay to measure mitochondrial respiration using the XF24
Analyzer. The major advantage of the method described is the
ability to run multiple samples (20) simultaneously using very small
quantities of material (1–10 mg per well). As a result, it is now
possible to perform types of investigations that require higher
throughput (for instance, drug screening and/or characterization)
and/or studies in which only a small amount of biological material
is available (e.g. a single mouse heart or a human muscle biopsy).
The optimal conditions for performing the assay were not
initially obvious, and they differ significantly from conventional
procedures using a chamber with a Clark-type oxygen electrode.
First, the mitochondria must be captured at the bottom of the
XF24 plate as opposed to being in suspension for conventional
polarography. Second, significantly higher levels of ADP, sub-
strates, and phosphate must be present to sustain respiratory rates.
This difference owes to the small volume of the chamber that is
Figure 6. Using the Coupling and Electron Flow assays in tandem to elucidate mechanistic activity of test agents. Coupling (A, C) and
electron flow experiments (B, D) were performed as described in Methods. Initial conditions are as follows (with final concentrations listed): A–B,
Controls (no additives) or 20 mM sodium azide or 4 mM antimycin-A; C–D, Controls (no additives) or 10 mM malonate or 2.5 mg/ml oligomycin or
2 mM rotenone. See text for further explanation of results.
doi:10.1371/journal.pone.0021746.g006
Figure 5. Comparison of Clark electrode and XF technology shows comparable respiration data between the methods. Mitochondria
isolated from rat heart and mouse liver were used in parallel coupling experiments using either a Hansatech or Rank Clark type electrode or the XF24.
Assays were performed as described in Methods for each platform, respectively. Comparison of Basal, State 3, State 4o and State 3u rates between
the Hansatech and XF with rat heart using or glutamate/malate as substrate (5A) or succinate/rotenone (5B), respectively. Comparison of Basal, State
3, State 4o and State 3u rates between the Rank and XF with mouse liver mitochondria using succinate/rotenone (5C). Data are expressed as mean 6
SD from 3 separate experiments in Fig 5A and B, and mean 6 SD from 4 experiments in 5C. The high SD in 5C owes to higher rates obtained with one
of the four mouse liver preps, rather than variation between methodologies on a given day. Data were analyzed using a two-factor ANOVA with
repeated measures on one factor. An interaction was detected only in the data of Fig. 5A, and post-hoc paired comparisons detected lower rates in
the XF24 of State 3 and 3u, and a higher rate of State 4o respiration with rat heart mitochondria oxidizing glutamate and malate (p,0.05).
doi:10.1371/journal.pone.0021746.g005
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7 ml). With 5 mg of mitochondria/well, the protein concentration
is 0.7 mg/ml, which is in the range of conditions employed in an
electrode chamber (typically 0.25–1 mg/ml depending upon the
mitochondrial tissue type). However, the total number of moles of
ADP, substrate or phosphate available over the measurement cycle
in this small volume is much less than a typical chamber of larger
volume. For instance, the total quantity of ADP available during
the measurement using 0.5 mM ADP in the assay medium is
only 3.5 nanomoles. If the State 3 rate of respiration of the
mitochondria is 836 pmoles/min (Fig. 6B), and provided that the
P:O ratio is approx 1.3 with succinate as substrate [25], then the
mitochondria have only enough ADP to sustain State 3 respiration
for approximately 2 minutes, which is evident in the tracing in
Fig. 3A. Thus, this small ‘closed’ chamber during measurement
accounts for the requirement of high concentrations of substrates,
phosphate and ADP.
It was necessary to include BSA in the experimental medium
with mouse liver mitochondria, as there was significant
uncoupling in its absence (Fig. 4B). This may relate to the length
of time that the mitochondria spend at 37uC over the course of
the experiment, which may be longer than in a conventional
electrode chamber. Such a requirement for BSA has generally
Figure 7. Assay Reproducibility. In 7A, intra-assay reproducibility is demonstrated. Assays used 3–5 replicate wells and well-to-well variation
within electron flow and coupling assays shows coefficients of variation (CV) ,17% in all measurements (except where OCR has been reduced to
minimal levels with rotenone or antimycin-A). In 7B, inter-assay reproducibility is demonstrated. Four separate uncoupling experiments from four
different preparations of mouse liver mitochondria were averaged to illustrate reproducibility of the assay over multiple days/preparations and shows
CVs ,20%. The corresponding table indicates the means, standard deviations and% CV, average RCR values are given in the text.
doi:10.1371/journal.pone.0021746.g007
Figure 8. Effects of Phosphatase Inhibitor (PPI) treatment on
rat heart mitochondrial respiration. Mitochondria were treated
with a cocktail of phosphatase inhibitors during the isolation procedure
as described in the Methods. Respiratory States 3, 4o and 3u were
measured in the presence (+PPI) or absence (-PPI) of phosphatase
inhibitor treatment in the presence of either succinate/rotenone (3 mg/
well) or glutamate/malate (6 mg/well) as oxidizable substrates, and rates
are expressed per mg mitochondrial protein.
doi:10.1371/journal.pone.0021746.g008
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a function of ongoing phospholipase activity. It should be
mentioned that the presence of BSA in the experimental media
shifts the dose response curve to FCCP (a hydrophobic
compound) far to the right, thus requiring higher concentrations
of FCCP to reach a maximal state 3u rate than in the absence
of BSA. It would be expected that the dose response curve of
other hydrophobic compounds in the assay would be similarly
affected.
We also did not anticipate that mitochondria would be
effectively captured and remain adherent throughout repeated
mixing and measurement cycles (Fig. 4). Like other tissue culture
plastic, the XF24 plates are plasma treated to create a hydrophilic
surface for cell adhesion. Tissue culture cell attachment is initially
tenuous, after which cells secrete extracellular matrix proteins for
which they express protein receptors that mediate spreading and
firm adhesion. The surface charge of mitochondria is negative,
largely as a result of the polar head groups of phospholipids [26].
This charge, similar to that of other biological membranes, is
apparently sufficient to allow mitochondria to adhere on the XF24
plate, and adhesion appeared to be unaffected by the reagents
added from the ports or by depolarization with uncoupler.
Surprisingly, we did not observe that coating the XF24 plate with
polyethyleneimine (a cation), or Cell-Tak
TM (a bioadhesive that
is a mixture of polyphenolic proteins from a marine mussel)
enhanced the maximal rate of respiration after centrifugation of
the mitochondria onto the plate (Fig. 4), thus implying that coating
did not increase mitochondrial adsorption. We did find that mouse
liver mitochondria that had been washed in a physiological salt-
containing buffer did not adhere as well as those isolated
exclusively in sucrose/mannitol (data not shown). Thus, the
adsorption of salt-washed mitochondria might benefit from the use
of an adhesive coating.
The respiratory rates with isolated rat heart and mouse liver
obtained with the XF24 using the described methodology were
generally comparable to rates obtained in Clark-type oxygen
electrode apparatuses (Fig. 5). The respiratory control ratio (state
3/state 4o) measured for mouse liver mitochondria at 37uC with
succinate as substrate was 3.960.6 (Fig. 7B). Most literature
values are based upon polarographic experiments performed at
either room temperature or at 30uC, which is generally
protective to mitochondria compared to 37uC, however, the
respiratory rates and RCR values reported here are comparable
to other reports of polarographic experiments performed at 37uC
[27–29]. Therefore, we believe that the method described here
can yield similar results to more conventional measures of mito-
chondrial oxygen consumption. In adapting this approach to
mitochondria from other tissues and species, mitochondrial
quantity, centrifugation volume, content and concentrations of
reagents in the assay medium, concentrations of respiratory
modulators (ADP, oligomycin, uncoupler) will need to be
optimized. Particular attention should be paid to incubation
conditions and the overall length of the experiment if using
mitochondria that rapidly decline in functional quality with time
after isolation.
In addition to demonstrating how this method could be used to
characterize potential toxicity or the mechanism of action of
compounds (Fig. 6), we also applied the approach to characterize
the effects of a cocktail of protein phosphatases on isolated rat
heart mitochondrial respiration (Fig. 8), in which we identified
a decreased rate of respiration with glutamate and malate but
not succinate as oxidizable substrates. During preparation of
this manuscript, a similar observation was reported by Hoppel
and colleagues [30]. Since early mass spectrometry-based
characterization of the heart mitochondrial proteome [31–32],
understanding of the complete set of proteins involved in the
function and regulation of heart mitochondria has rapidly
advanced [33–34]. Endogenous phosphorylation of multiple
mitochondrial proteins and complexes have been described
[35–41], and characterization of regulatory post-translational
modifications that integrate bioenergetics and cell signaling is an
area of active discovery. Here, we demonstrate how the
described method could be used to assess functional consequenc-
es of manipulation of post-translational modifications in isolated
mitochondria. As employed, the mixture of protein phosphatases
likely inhibited ongoing protein tyrosine phosphatase activity,
and members of the protein tyrosine phosphatase family have
been localized to mitochondria [36,37,42,43]. Phosphotyrosine
modification has been documented in complex I and in specific
steps of the pathway of glutamate/malate oxidation in the TCA
cycle [40,41] that could potentially account for our observed
alterations in respiratory rates. Further proteomic analysis would
be required to establish how the phosphatase inhibitor treatment
employed here altered the phosphorylation status of mitochon-
drial proteins. As well, the assay described here could be
performed with alternative Complex I dependent oxidizable
substrates to further identify the locus of the effects of phos-
phatase inhibitors.
In summary, this report provides details of a powerful and novel
approach for monitoring mitochondrial respiration and peri-
mitochondrial pH changes in relative high throughput with
minute quantities of isolated mitochondria. Such an assay lends
itself to drug screening or identification of effects of altered gene
expression or in vivo treatment on the function of subsequently
isolated mitochondria. In fact, preliminary data suggest that the
XF96 analyzer can be similarly employed with isolated mitochon-
dria. The basic workflow and assay design is identical, however, as
the wells of the XF96 plates are 40% of the surface area of the
XF24 well plates, it was observed that optimal quantities of
mitochondria to use ranged from ,0.5–5 mg per well (data not
shown). In general, the small amounts of mitochondria required
for this new assay make it possible to simultaneously gather
information on mitochondria isolated from single organs of a
mouse or from cultured cells. Within the same plate, as
demonstrated in Fig. 6, effects on different sites in the electron
transport chain can be probed, and the mechanism of action of a
drug or gene product on oxidation of a variety of substrates (such
as pyruvate/malate, fatty acyl carnitine/malate, glycerol-3-phos-
phate, etc) can be determined simultaneously. The concurrent
acquisition of data is advantageous in particular for mitochondria
that decline in quality over the course of the experimental day
following isolation. Overall, we propose that this new methodology
can be a valuable tool for the discovery of mitochondrial-targeted
therapeutics and the elucidation of mitochondrial-related cell
signaling, as well as pathogenesis in a broad variety of conditions
including metabolic,cardiovascular and mitochondrial diseases,
neurodegeneration, and cancer biology.
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